Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
68.49 CHF | -1.53% | -.--% | -.--% |
May. 29 | UBS Adjusts DuPont de Nemours Price Target to $98 From $93, Maintains Buy Rating | MT |
May. 28 | DuPont's Breakup Plan Holds Logic Amid Disadvantages, BofA Says | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past twelve months, EPS forecast has been revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.32 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 3.24 times its current sales, is high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Diversified Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 34.35B | - | ||
+0.61% | 74.34B | B | ||
-1.15% | 46.86B | A- | ||
+9.93% | 18.1B | B | ||
+12.37% | 11.92B | A- | ||
-1.56% | 10.43B | - | ||
-21.37% | 10.33B | B | ||
-0.19% | 9.04B | A- | ||
-8.59% | 7.84B | C- | ||
-2.25% | 7.52B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- DD Stock
- 6D81 Stock
- Ratings DuPont de Nemours, Inc.